In NSCLC cells with loss of FBXW7, treatment with Entinostat, a class 1 HDAC inhibitor, effectively overcame Taxol resistance and may be beneficial in treating aggressive Taxol-resistant NSCLCs and hematological cancer cells that lack expression of FBXW7 [165,166,167]. Here, FBXW7 is linked to non-small cell lung carcinoma.